RESUMEN
Background: genital warts are the most common viral sexually transmitted disease affecting 1% of the population. A prospective, open-label controlled trial was performed to compare topical 5% potassium hydroxide [KOH] solution with CO[2] laser in the treatment of female genital warts
Methods: seventy patients were enrolled in the study after convenience sampling. Right-sided lesions of the patients were treated by CO[2] laser every 3 weeks. The left-sided lesions of the same patients were treated by topical 5% KOH solution twice a day using a toothpick with cotton wrap on the tip. The patients were visited at 3, 6, and 9 weeks after initiation of the treatment and followed up for 6 months after the last visit
Results: out of seventy patients, sixty three completed the study and were analyzed. A total of 56 KOH treated-patients [88.9%] showed complete response. On the other hand, 56 laser-treated patients [88.9%] presented complete clearing of the lesion. There was not any difference in response to both modalities of treatment. Complications of KOH solution and CO[2] laser were 24% and 19% respectively [P>0.05], but serious adverse events were not observed. The patients under KOH treatment displayed a recurrence rate of 11.1% [7 cases], while the same patients with CO[2] laser therapy demonstrated a recurrence rate of 7.9% [5 cases] [P=0.54]
Conclusion: topical 5% KOH solution was as effective as CO[2] laser in the treatment of female genital warts. There was not any serious complication in the application of KOH solution. This could be used as a new treatment for genital warts
RESUMEN
In order to evaluate the role of ketoconazole in the prevention of ovarian hyperstimulation syndrome [OHSS] in women with polycystic ovary syndrome [PCOS] undergoing ovarian stimulation with gonadotropins, a prospective, random-ized, double-blind, placebo controlled study was done on one-hundred and nine PCOS women that had been referred to be treated by gonadotropins.All 109 women were assigned for random allocation. Group A [50 patients] received two ampoules of hMG beginning on day 2 or 3 of the cycle and ketoconazole [50 mg/every 48 hours] starting on the first day of hMG treatment. Group B [51 patients] received the same protocol of hMG combined with one tablet of placebo every 48 hours. Main outcome measures were follicular development, E2 levels, and pregnancy rate.The total number of hMG ampoules and duration of treatment to attain ovarian stimulation was higher in group A [p<0.0001]. Serum E2 level and number of patients with dominant follicles on day 9 of the cycle were higher in group B [p<0.0001]. There was no significant difference between serum E2 level and total number of follicles at the time of hCG administration in the two groups. The cancellation rate and OHSS rate were similar in the two groups.Ketoconazole has no effect in prevention of OHSS in PCOS patients undergoing ovarian stimulation. It may however reduce the rate of folliculogenesis and steroidogenesis